A Phase 3 interventional study of Liraglutide injection and Placebo injection in Delirium, Postoperative, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Emergence Delirium with a site in China — 64 open to participants now, 65 under way, 1 of them phase 3. Emergence Delirium · China.
Among the 185 studies in Emergence Delirium with a site in China, this one is the 46th largest by planned enrollment of the 111 interventional ones that give a count, is one of 30 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 47 of the 64 other live ones, and was the 102nd registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →64 of the 185 studies in Emergence Delirium with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 65–85
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 65–90 · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 65+ · Healthy volunteers
Peking University People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
Fujian Medical University Union Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 30 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 225 across the 111 interventional studies, 300 across the 74 observational. Of the 74 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 185 have an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 251 studies on the registry; 148 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 1 study filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
21 of the studies in Emergence Delirium with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06361238Phase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery | 2027-03-31 |
| NCT07880938The First Hospital of Jilin UniversityIntranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy | 2026-12 |
| NCT07523334Peking University First HospitalImpact of Esketamine on Delayed Neurocognitive Recovery in Older Patients | 2026-12 |
| NCT07351474The First Affiliated Hospital with Nanjing Medical UniversityRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | 2026-12-25 |
| NCT07394647The First Affiliated Hospital of Zhejiang Chinese Medical UniversityTranscutaneous Auricular Vagus Nerve Stimulation for Prevention of Emergence Agitation and Delirium in Children Undergoing Tonsillectomy and Adenoidectomy | 2026-12-30 |
Add all 21 to your calendar (.ics) → With an account.
Among the 185 studies in Emergence Delirium with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Delirium is the most prevalent neurological complication following cardiac surgery. It is characterized by an acute and fluctuating disturbance in consciousness, attention, and cognitive function. The incidence of delirium post-cardiac surgery ranges between 11% and 46%. It is closely linked to increased postoperative mortality, extended hospital stays, higher healthcare costs, and long-term cognitive impairment. Currently, it is widely recognized that the development of delirium is influenced by multiple factors, including advanced age, diabetes, surgical and anesthetic techniques, depression, baseline cognitive function, and infections, among others.
Inflammatory responses, crucial for protecting against external or internal threats, can, following surgery, lead to neuroinflammation and neurological damage due to elevated postoperative inflammatory markers and blood-brain barrier disruption. The involvement of microglia and astrocytes, key players in the central nervous system's immune response, has been identified in mediating postoperative delirium, making them potential targets for prevention.
Liraglutide, a Glucagon-like peptide-1 receptor agonist primarily used for treating Type 2 diabetes, has shown promise in mitigating neurocognitive damage associated with diabetes and Alzheimer's disease, suggesting its potential in preventing postoperative delirium in cardiac surgery patients with Type 2 diabetes. Preliminary animal studies and a randomized controlled trial indicate that perioperative liraglutide application could reduce the incidence of postoperative delirium by inhibiting glial activation and the subsequent neuroinflammatory response. However, differences in patient demographics, disease severity, and dosing in previous studies highlight the need for further investigation.
The study aims to investigate whether the perioperative administration of liraglutide can prevent the onset of postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery. Secondary objectives include assessing the impact on the severity and duration of delirium, cognitive function, anxiety, depression, cardiac function, cardiovascular events, ICU stay, mechanical ventilation duration, and levels of serum markers for brain injury, inflammation, myocardial damage, and cardiac function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection of liraglutide
Drug: Liraglutide injection
Subcutaneous injection of vehicle
Drug: Placebo injection
Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
Also known as: Victoza
Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Also known as: Normal saline
The incidence of delirium
Confusion Assessment Method (CAM), or its variant for the Intensive Care Unit, known as CAM-ICU, is the tool used to assess the incidence of delirium. For CAM, the scale ranges from a minimum value of 11 to a maximum of 44, with higher scores indicating a worse outcome. In contrast, CAM-ICU does not utilize a numerical scale; it is a qualitative assessment designed to evaluate confusion without assigning specific values.
Time frame: One day before surgery and within the first seven days after surgery.
The severity of delirium
The CAM-Severity Scale (CAM-S), available in both short-form and long-form versions, serves as a tool for assessing the severity of delirium. The scale extends from 0 to 7 in its short-form and from 0 to 19 in its long-form. Higher scores on the CAM-S are indicative of more severe outcomes.
Time frame: One day before surgery and within the first seven days after surgery.
Cognitive function
Minimum Mental State Examination (MMSE) is the tool used to assess cognitive function. The scale extends from 0 to 30, with higher scores indicating a better outcome.
Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Anxiety
Generalized anxiety disorder-7 (GAD-7) is the tool used to assess anxiety. The scale extends from 0 to 21, with higher scores indicating a worse outcome.
Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Depression
Patient Health Questionnaire-9 (PHQ-9) is the tool used to assess depression. The scale extends from 0 to 27, with higher scores indicating a worse outcome.
Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Duration of ICU stay
By retrieving the Hospital Information System and ICU special care sheet
Time frame: The time from transfer into the ICU to discharge from the ICU, assessed up to 12months.
Mechanical ventilation time
By retrieving the Hospital Information System and ICU special care sheet
Time frame: The time from tracheal intubation to the removal of the tracheal tube, assessed up to 12months.
Duration of hospital stay
By retrieving the Hospital Information System
Time frame: The time from hospital admission to discharge, assessed up to 12months.
In-hospital mortality
By retrieving the Hospital Information System
Time frame: The time from hospital admission to discharge, assessed up to 12months.
Incidence of adverse events
By retrieving the Hospital Information System, ICU special care sheet and follow-up
Time frame: One day preoperatively to three days Postoperatively.
Rate of major cardiovascular adverse events
By retrieving the Hospital Information System, ICU special care sheet and follow-up
Time frame: Within 1 year post-surgery (including cardiovascular death, myocardial infarction, and stroke)
Serum levels of NSE
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of CRP
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of IL-1α
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of TNF-α
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of C3
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of LDH
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of CK
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of CK-MB
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of AST
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of cTNT
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of BNP
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of C1q
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of IL-1β
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of IL-6
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Serum levels of S100β
ELISA
Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively
Left Ventricular Posterior Wall Thickness in Diastole (LVPWTd)
The echocardiography is used to assess the LVPWTd.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Left Ventricular End-Diastolic Dimension (LVDd)
The echocardiography is used to assess the LVDd.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Left Ventricular End-Systolic Diameter (LVDs)
The echocardiography is used to assess the LVDs.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Left Atrial Diameter (LAD)
The echocardiography is used to assess the LAD.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Ejection Fraction (EF)
The echocardiography is used to assess the EF.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Fractional Shortening (FS)
The echocardiography is used to assess the FS.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Early Diastolic Velocity/Atrial Diastolic Velocity (E/A)
The echocardiography is used to assess the E/A.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Interventricular Septum Thickness in Diastolic (IVSTd)
The echocardiography is used to assess the IVSTd.
Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →